MOSCOW, October 31, 2013 /PRNewswire/ --
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Russia's International Biotechnology Center (IBC) Generium, has signed an agreement to grant access to ScienceDirect and Embase for its scientists.
Access to ScienceDirect, Elsevier's full-text platform for scientific, technical and medical research literature and Embase, the most comprehensive international database for biomedical researchers, supports the company's strategy to maintain its leading position in Russia in generic drug development and innovate in biotechnological therapies.
Established in 2011, Generium has a unique and extensive portfolio of innovative drugs and biotechnological therapies. Generium's aim is to innovate in biotechnological therapies against diseases such as oncology as well as cardio-vascular, neurodegenerative and autoimmune disorders. The center's research and development teams will benefit greatly from its newly acquired access to ScienceDirect and Embase, by providing them with peer-reviewed full-text research papers published in more than 2000 international journals, as well as timely access to biomedical information.Dr. Andrei Petrov, Chief Scientific Officer of Generium, said, "We are delighted to reach this agreement with Elsevier providing our research and development teams with online access to an extensive stream of world-class scientific content which will substantially facilitate our own research on drug discovery and development. We consider both ScienceDirect and Embase as critical tools for strengthening our competitive position." Igor Osipov, PhD, Elsevier Regional Director for Russia and Belarus said, "We are honored to work with Generium, marking our first collaboration within the corporate market for biotechnology in Russia. We are confident that access to ScienceDirect and Embase will help Generium to continuously innovate and expand their line of products." About Generium
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts